Primary Sclerosing Cholangitis (PSC) refers to a chronic inflammatory disease of the bile ducts that leads to scarring and narrowing of the bile ducts over many years. Some key features of PSC include abnormal narrowing and stricturing of the intrahepatic and extrahepatic bile ducts. While the exact causes remain unknown, it is considered an autoimmune disorder where the body's immune system attacks the bile ducts, causing scarring and inflammation. The condition is commonly seen in association with inflammatory bowel disease (IBD). Early diagnosis of PSC is crucial to slow progression and optimal management. Improved non-invasive diagnostic techniques along with novel therapeutics in testing phases are augmenting treatment approaches.
The global Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 1.98 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The development of novel diagnostic techniques has accelerated diagnosis capabilities. Advanced blood-based biomarker assays and MRI-based techniques provide enhanced diagnostic accuracy compared to conventional modalities like ERCP. For instance, enhanced liver fibrosis (ELF) panels and MRI cholangiography can delineate early-stage disease. On the treatment front, cell-based therapies aimed at modulating the immune response are in testing phases. BT-11, an autologous nonmyeloablative hematopoietic stem cell transplant by NGM Biopharmaceuticals demonstrated significant antithetical effects versus placebo in phase 2 studies. Targeted therapies against key mediators of bile duct injury are also under investigation.
Segment Analysis
The global primary sclerosing cholangitis market is divided into four key segments based on drug class, route of administration, distribution channel, and region. The drug class segment is further divided into ursodeoxycholic acid, obeticholic acid, and other drug classes. Among these, ursodeoxycholic acid dominates the market as it is currently the only approved drug for treating primary sclerosing cholangitis. It helps in reducing symptoms and slowing disease progression.
The route of administration segment is divided into oral and injectable. Currently, the oral segment dominates as most of the available drugs are administered orally in the form of pills or capsules. However, injectable segment is expected to grow at a higher rate due to the availability of therapies in late stage clinical trials.
Key Takeaways
The global Primary Sclerosing Cholangitis Market Growth is expected to witness high growth over the forecast period of 2023 to 2030. The growing geriatric population and rising prevalence of inflammatory bowel diseases is driving the market. The global Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 1.98 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030.
Regional analysis - North America currently generates the highest revenue and is expected to continue its dominance over the forecast period. This is attributed to the rising awareness about the disease, strong healthcare infrastructure, and presence of major market players in the region. The Asia Pacific region is anticipated to witness the fastest growth rate owing to growing healthcare expenditure, increasing medical tourism, and improving access to diagnosis and treatment.
Key players - Key players operating in the primary sclerosing cholangitis market are Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd. The players are increasingly focusing on developing novel treatments such as monoclonal antibodies, RNAi therapies, and antifibrotic drugs to expand their product portfolios.
For more insights, read- https://www.ukwebwire.com/primary-sclerosing-cholangitis-market-trends-size-and-share-analysis/
Comments
0 comment